Effect of Cumin on prediabetic patients.

Effects of Cumin (Cuminum cyminum) soft capsule on glycemic markers, lipid profile, and leptin in prediabetic patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016111930962N1

Enrollment

Registered

2017-02-19

Start date

2017-01-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre diabetes. Abnormal glucose tolerance test

Interventions

Intervention 1: The intervention group will receive75 mg cumin soft gel (25 mg TID). . The intervention period will lunched 10 weeks. Intervention 2: The control group will receive placebo (the same a

Placebo

The intervention group will receive75 mg cumin soft gel (25 mg TID). . The intervention period will lunched 10 weeks

The control group will receive placebo (the same as cumin soft gel) before each meal for 10 weeks.

Eligibility

Sex/Gender

All

Age

20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: FBS between 100-125mg/dl or 2 hours after GTT (75mg glucose) BS between 140-199 mgldl or HbA1C between 5.7-6.7; Patients without liver, renal, or endocrine disorders or malignancy; Patients who do not use any drugs with significant interaction with cumin like anti-depressant; Willing to participation and filling the written consent Exclusion criteria: not willing to participation; disobedience from the study protocol; having special diets; any liver, renal, or endocrine disorders or malignancy during the intervention; consuming vitamin D, omega-3, selenium, or anti-depressant drugs; change in the drug history during the intervention 7- using insulin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FBS (glycemic index). Timepoint: Before (day 0) and after intervention (after 10 weeks intervention). Method of measurement: Valid biochemistry kits (Pars Azmoon).;HbA1C (glycemic index). Timepoint: Before (day 0) and after intervention (after 10 weeks intervention). Method of measurement: Valid biochemistry kits (Pars Azmoon).;Insulin (glycemic index). Timepoint: Before (day 0) and after intervention (after 10 weeks intervention). Method of measurement: Valid biochemistry kits (Pars Azmoon).	—

Measure

Time frame

FBS (glycemic index). Timepoint: Before (day 0) and after intervention (after 10 weeks intervention). Method of measurement: Valid biochemistry kits (Pars Azmoon).;HbA1C (glycemic index). Timepoint: Before (day 0) and after intervention (after 10 weeks intervention). Method of measurement: Valid biochemistry kits (Pars Azmoon).;Insulin (glycemic index). Timepoint: Before (day 0) and after intervention (after 10 weeks intervention). Method of measurement: Valid biochemistry kits (Pars Azmoon).

—

Secondary

Measure	Time frame
Lipid profile. Timepoint: Before and after intervention. Method of measurement: Valid biochemistry tests.;Serum leptin. Timepoint: Before and after intervention. Method of measurement: Elisa kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTina Jafari

Shahrekord University of Medical Sciences

t.jafari@skums.ac.irtinajafari15@yahoo.com+98 38 3333 3815

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026